Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,118
  • Shares Outstanding, K 216,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -79,980 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.71
  • Price/Sales 465.47
  • Price/Cash Flow N/A
  • Price/Book 2.72
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.43
  • Most Recent Earnings $-0.10 on 05/06/21
  • Next Earnings Date 02/24/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.11
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7703 +12.38%
on 01/24/22
1.2500 -30.74%
on 12/27/21
-0.3943 (-31.29%)
since 12/23/21
3-Month
0.7703 +12.38%
on 01/24/22
1.6800 -48.47%
on 11/05/21
-0.6143 (-41.51%)
since 10/26/21
52-Week
0.7703 +12.38%
on 01/24/22
5.9500 -85.45%
on 02/10/21
-2.6843 (-75.61%)
since 01/26/21

Most Recent Stories

More News
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose...

ZIOP : 0.8657 (-0.88%)
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biotech saw a slight bounce-back from its lows of last week.

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of...

ZIOP : 0.8657 (-0.88%)
Ziopharm: Q3 Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Monday reported a loss of $22.7 million in its third quarter.

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for...

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report...

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

• Over 50% reduction in personnel

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology to Participate in September Investor Conferences

BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer...

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles

ZIOP : 0.8657 (-0.88%)
Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates

Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data

ZIOP : 0.8657 (-0.88%)

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

3rd Resistance Point 1.0457
2nd Resistance Point 1.0078
1st Resistance Point 0.9368
Last Price 0.8657
1st Support Level 0.8279
2nd Support Level 0.7900
3rd Support Level 0.7190

See More

52-Week High 5.9500
Fibonacci 61.8% 3.9714
Fibonacci 50% 3.3601
Fibonacci 38.2% 2.7489
Last Price 0.8657
52-Week Low 0.7703

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar